OLMA insider Shane Kovacs sells shares via Form 144

Shane W. Kovacs reported sales of Common Stock as shown on a Form 144.

Rhea-AI Filing Summary

Shane W. Kovacs reported sales of Common Stock as shown on a Form 144. The filing lists multiple dispositions, including 100,000 shares on 01/15/2026 and 241,999 shares on 03/09/2026. The table shows share counts and gross proceeds for each sale between 01/13/2026 and 03/09/2026.

Insights

Corporate Governance Analyst

Routine insider dispositions are disclosed; amounts are itemized across several dates.

The excerpt lists multiple open‑market dispositions by Shane W. Kovacs of Common Stock with per‑trade share counts and gross proceeds (e.g., $2,873,214.99 for 100,000 shares on 01/15/2026). These entries reflect reported sales activity rather than corporate actions.

Remaining implications depend on total holdings after the trades and any Rule 10b5‑1 plan language, which is not shown in the excerpt. Subsequent filings may provide net position or plan disclosures.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OLMA insider Shane W. Kovacs disclose on Form 144?

The filing discloses multiple sales of Common Stock by Shane W. Kovacs. It lists specific trades with dates, share counts, and gross proceeds between 01/13/2026 and 03/09/2026.

How many shares did Shane W. Kovacs sell on 01/15/2026 for OLMA?

On 01/15/2026 the filing shows a sale of 100,000 shares with gross proceeds of $2,873,214.99. The entry appears in the Form 144 table of dispositions.

Does the excerpt show proceeds for the March 9, 2026 sale by OLMA insider?

Yes. The entry for 03/09/2026 shows a sale of 241,999 shares with gross proceeds of $3,254,934.55 listed in the table of securities sold.

Are the sales in the excerpt described as issuer transactions or open‑market sales?

The table lists the transactions under securities sold by the reporting person; the entries show share counts and proceeds but do not state whether sales were open‑market or otherwise in the provided excerpt.

Does the Form 144 excerpt disclose remaining ownership after these sales?

The excerpt enumerates sales with dates, shares, and proceeds but does not report total shares held following these transactions in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 12:27 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001579397
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Olema Pharmaceuticals, Inc.
SEC File Number	001-39712
Address of Issuer	780 BRANNAN STREET SAN FRANCISCO CALIFORNIA 94103
Phone	(415) 651-3316
Name of Person for Whose Account the Securities are To Be Sold	Kovacs Shane William Charles
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	53206	904566.21	68659923	03/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2020	Restricted Stock Vesting	Issuer			48206	06/15/2020	Compensation
Common	11/15/2022	ESPP Purchase	Issuer			5000	11/15/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	01/13/2026	3822	107069.20
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	01/15/2026	100000	2873214.99
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	02/12/2026	10000	238498.19
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	02/23/2026	30000	723007.46
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	02/24/2026	20000	500002.00
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	02/27/2026	6521	163026.25
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	03/04/2026	20000	488653.67
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	03/09/2026	241999	3254934.55

144: Remarks and Signature

Remarks
Date of Notice	03/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Shane W. Kovacs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)